Satellos Granted US Patent Covering Lead Drug Candidate Forazapadin And Broader AAK1 Inhibitor Platform

Satellos Bioscience Inc. has been granted U.S. Patent No. 12,747,245 by the United States Patent and Trademark Office, covering its lead drug candidate forazapadin and a broader class of AAK1 inhibitors. This patent provides intellectual property protection until September 6, 2044, with the possibility of a Patent Term Extension following future U.S. marketing approval. The company focuses on developing treatments for degenerative muscle diseases.